Pacira BioSciencesFRA:82P +2.75%75 PS Ratio is 1.54 as of Jul. 08, 2026, which is 66% below its 10-year median of 4.52. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review. Among 952 Drug Manufacturers companies, Pacira BioSciences ranks better than 63.66% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pacira BioSciences's share price is €22.40.
Pacira BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €14.56. Hence, Pacira BioSciences's PS Ratio for today is 1.54.
The historical rank and industry rank for Pacira BioSciences's PS Ratio or its related term are showing as below:
FRA:82P'
s PS Ratio Range Over the Past 10 Years
Min: 0.94 Med: 4.52 Max: 7.82
Current: 1.52
During the past 13 years, Pacira BioSciences's highest PS Ratio was 7.82. The lowest was 0.94. And the median was 4.52.
FRA:82P's PS Ratio is ranked better than 63.66% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs FRA:82P: 1.52
During the past 12 months, the average Revenue per Share Growth Rate of Pacira BioSciences was 14.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.30% per year.
During the past 13 years, Pacira BioSciences's highest 3-Year average Revenue per Share Growth Rate was 80.40% per year. The lowest was -66.90% per year. And the median was 11.00% per year.
Back to Basics: PS Ratio
Pacira BioSciences (FRA:82P) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Pacira BioSciences PS Ratio Related Terms
Pacira BioSciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pacira BioSciences's Share Price of today is €22.40. Pacira BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.56.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pacira BioSciences (FRA:82P) has a PS Ratio of 1.54 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pacira BioSciences and its competitors. This is 66% below median its historical median of 4.52. Over the past decade, Pacira BioSciences' PS Ratio has ranged from 0.94 to 7.82. According to the industry distribution chart, Pacira BioSciences ranks #346 out of 952 companies in the Drug Manufacturers industry, placing it in the top 36.3%.
Is Pacira BioSciences' PS Ratio too high?
Pacira BioSciences' current PS Ratio of 1.54 is 66% below median its 10-year median of 4.52. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 7.82. The Drug Manufacturers industry median PS Ratio is 2.29. Pacira BioSciences' value of 1.54 is 32.8% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #346 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' PS Ratio compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #346 out of 952 companies for PS Ratio. This puts Pacira BioSciences in the upper half of its industry. The industry median PS Ratio is 2.29. Pacira BioSciences' value of 1.54 is 32.8% below this benchmark. Historically, Pacira BioSciences' own PS Ratio has ranged from 0.94 to 7.82 over the past decade. While the company's 10-year median is 4.52 vs. the industry median of 2.29, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.29, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current PS Ratio of 1.54 is 32.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current PS Ratio is 1.54, which is 66% below median its own 10-year median of 4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current PS Ratio of 1.54. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current PS Ratio is 1.54, which is 66% below median its 10-year median of 4.52 and 32.8% below the Drug Manufacturers industry median of 2.29. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current PS Ratio is 1.54 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.
Key valuation signals for FRA:82P:
PS Ratio: 1.54 (66% below median its 10-year median of 4.52)
GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
Industry Position: 32.8% below the Drug Manufacturers median (#346 of 952)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score
Get the complete analysis for FRA:82P
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
